The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Imagine if you can get your $100 million athlete back before the end of the season,” said Dr. Paul Liu, executive chairman of Pax Therapeutics.

Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

The U.S. Food and Drug Administration (FDA) issued new draft guidance on October 29, 2025, proposing what it said were “major updates to ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...

“This human-first approach is underpinned by the company’s Kabegoe philosophy, meaning ‘overcoming barriers’,” explains Dr Miyamoto. “It’s a mindset that guides everything from R&D to leadership, and ...

Parents are set up to fail here. They are not given a lot of scientific education, they are told go home and do your own ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced ...